Ann: Updated guidance for PAT-DX1 phase 1 clinical study, page-43

Thinking that a delay in a companies previously cited ' on track' process will entice big pharma to try and look at purchasing it more cheaply is A+ grade copium.

Acquisition etc simply don't work like that.

To be picked up, you need to produce results.
usually phase 3 results.

To produce results, you need product.

PAT-DX1 is delayed for a phase 1 trial due to this manufacturing delay.

Yes, I'm aware that DX3 is what many consider to be the big ticket item, but trying to spin a manufacturing delay as a positive for any potential bigger company sniffing around is just foolish.